A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

NCT06444451 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Alopecia Areata

Interventions

DRUG: Amlitelimab
DRUG: Placebo

Sponsor

Sanofi